India Exchange Filings

NATCO Pharma US FDA Inspection Update

Natco Pharma Ltd receives seven Form 483 observations after US FDA inspection of its Kothur facility

  • Inspection ran from November 12 to 20, 2026, at the formulation manufacturing facility in Kothur, Hyderabad.
  • The company described the observations as procedural and said it was confident of addressing them within the stipulated timelines.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.